Market open
NeoGenomics/$NEO
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About NeoGenomics
NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Advanced Diagnostics. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. Advanced Diagnostics segment supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. For Clinical Services, Its specialized diagnostic services are performed based on an online test order or a written test requisition form. The company generates majority of its revenue from Clinical Services.
Ticker
$NEO
Sector
Trading on
Industry
Health Care Providers & Services
Headquarters
Employees
2,100
Website
NeoGenomics Metrics
BasicAdvanced
$2.4B
Market cap
-
P/E ratio
-$0.62
EPS
1.18
Beta
-
Dividend rate
Price and volume
Market cap
$2.4B
Beta
1.18
52-week high
$21.22
52-week low
$12.77
Average daily volume
697K
Financial strength
Current ratio
1.991
Quick ratio
1.819
Long term debt to equity
44.277
Total debt to equity
66.754
Interest coverage (TTM)
-10.83%
Management effectiveness
Return on assets (TTM)
-2.72%
Return on equity (TTM)
-8.38%
Valuation
Price to revenue (TTM)
3.615
Price to book
2.6
Price to tangible book (TTM)
63.1
Price to free cash flow (TTM)
-108.25
Growth
Revenue change (TTM)
12.06%
Earnings per share change (TTM)
-20.17%
3-year revenue growth (CAGR)
9.95%
3-year earnings per share growth (CAGR)
15.14%
What the Analysts think about NeoGenomics
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for NeoGenomics stock.
NeoGenomics Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
NeoGenomics Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
NeoGenomics News
AllArticlesVideos
NeoGenomics' Newly Published Study Underscores Potential of ctDNA as a Predictive Tool for Monitoring Patients with High-Risk Melanoma
Business Wire·4 hours ago
ConcertAI and NeoGenomics Announce New AI Software-as-a-Service Solution for Hematology Clinical Research
Business Wire·6 days ago
NeoGenomics, Inc. (NEO) Q3 2024 Earnings Call Transcript
Seeking Alpha·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for NeoGenomics stock?
NeoGenomics (NEO) has a market cap of $2.4B as of December 11, 2024.
What is the P/E ratio for NeoGenomics stock?
The price to earnings (P/E) ratio for NeoGenomics (NEO) stock is 0 as of December 11, 2024.
Does NeoGenomics stock pay dividends?
No, NeoGenomics (NEO) stock does not pay dividends to its shareholders as of December 11, 2024.
When is the next NeoGenomics dividend payment date?
NeoGenomics (NEO) stock does not pay dividends to its shareholders.
What is the beta indicator for NeoGenomics?
NeoGenomics (NEO) has a beta rating of 1.18. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.